Shares of BioSpecifics Technologies Corp (NASDAQ:BSTC) have been given a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.

Brokers have set a twelve-month consensus price target of $72.00 for the company and are predicting that the company will post $0.39 earnings per share for the current quarter, according to Zacks. Zacks has also assigned BioSpecifics Technologies Corp an industry rank of 156 out of 265 based on the ratings given to its competitors.

Separately, Zacks Investment Research downgraded BioSpecifics Technologies Corp from a “hold” rating to a “sell” rating in a research report on Monday, May 15th.

BioSpecifics Technologies Corp (BSTC) traded up 0.55% during trading on Thursday, reaching $49.55. The company had a trading volume of 1,994 shares. The stock has a market cap of $355.32 million, a PE ratio of 30.40 and a beta of 1.77. The company has a 50-day moving average price of $52.09 and a 200 day moving average price of $52.80. BioSpecifics Technologies Corp has a 52-week low of $35.59 and a 52-week high of $58.79.

WARNING: This news story was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/06/22/biospecifics-technologies-corp-bstc-receives-average-rating-of-strong-buy-from-brokerages.html.

A number of large investors have recently added to or reduced their stakes in BSTC. Bank of America Corp DE increased its stake in BioSpecifics Technologies Corp by 122.6% in the first quarter. Bank of America Corp DE now owns 2,489 shares of the biopharmaceutical company’s stock worth $137,000 after buying an additional 1,371 shares during the period. American International Group Inc. increased its stake in BioSpecifics Technologies Corp by 7.1% in the first quarter. American International Group Inc. now owns 3,327 shares of the biopharmaceutical company’s stock worth $182,000 after buying an additional 222 shares during the period. Public Employees Retirement System of Ohio increased its stake in BioSpecifics Technologies Corp by 16.2% in the first quarter. Public Employees Retirement System of Ohio now owns 3,674 shares of the biopharmaceutical company’s stock worth $201,000 after buying an additional 513 shares during the period. A.R.T. Advisors LLC purchased a new stake in BioSpecifics Technologies Corp during the fourth quarter worth $206,000. Finally, Bank of Montreal Can increased its stake in BioSpecifics Technologies Corp by 10.6% in the first quarter. Bank of Montreal Can now owns 7,272 shares of the biopharmaceutical company’s stock worth $398,000 after buying an additional 699 shares during the period. 55.74% of the stock is currently owned by institutional investors and hedge funds.

About BioSpecifics Technologies Corp

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.

Get a free copy of the Zacks research report on BioSpecifics Technologies Corp (BSTC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioSpecifics Technologies Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies Corp and related companies with MarketBeat.com's FREE daily email newsletter.